Two strands of recent research are pushing the study of mental health in unfamiliar directions at once — one reaching back into psychoanalytic theory, the other into cellular energy metabolism — and together they widen the frame through which depression and the unconscious mind are being understood.
The first comes from the University of Oslo, where researchers argue in the journal Entropy that the dominant contemporary model of the brain — as a prediction machine that continuously anticipates the world and updates itself against error — closely echoes ideas Sigmund Freud advanced more than a century ago. Rather than treating psychoanalysis as a historical curiosity, the paper positions Freud’s model of the mind as an early anticipation of predictive-processing neuroscience, reopening a serious conversation about unconscious inference that many in the field had considered closed. The claim is interpretive rather than experimental, but it signals a renewed willingness among neuroscientists to mine older theoretical traditions for testable structure.
The second strand is empirical and more cautious. A systematic review from the University of Ottawa, published in Brain Medicine, examined five randomised controlled trials involving 238 participants across South Korea, the United States, Brazil, India and Israel, testing creatine — a compound long familiar as an athletic supplement — as an add-on to depression treatment. The results were mixed. Two trials, both in women with major depressive disorder, found that adding creatine to an antidepressant or to cognitive behavioural therapy improved symptoms; three others, including one in bipolar disorder, found no meaningful benefit.
The proposed mechanism is metabolic: creatine supports the brain’s energy production, and researchers hypothesise that restoring cellular energy balance may ease depressive symptoms in some patients, particularly those for whom standard antidepressants have failed. The evidence remains preliminary, the trials small, and the reviewers stopped well short of endorsement, calling for larger and more rigorous studies before creatine could be considered an established adjunct.
Taken together, the two developments sketch a discipline broadening its explanatory vocabulary — willing to revisit the psychoanalytic account of hidden mental processes while simultaneously probing the physical energetics of the depressed brain. Neither line of work delivers a settled answer, and both carry the caveats appropriate to early-stage science. For clinicians and patients, the practical implications are modest for now; the significance lies in a field enlarging the questions it is prepared to ask.
– Rithvisha Kiran
